NCT02005991View on ClinicalTrials.gov

A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

PF-05212377

Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.

DRUG

PF-05212377

Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.

DRUG

PF-05212377

Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.

Trial Locations (3)

06511

Pfizer Investigational Site, New Haven

06519

Pfizer Investigational Site, New Haven

06520

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02005991 - A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377 | Biotech Hunter | Biotech Hunter